Gastric Ulcers
Overview
Gastric and duodenal ulcers result from breakdown of the mucosal protective barrier, commonly caused by H. pylori infection, chronic NSAID use, or stress. BPC-157 (Body Protective Compound 157) was originally isolated from gastric juice and has an extraordinarily rich evidence base for gastroprotection and ulcer healing. Oral administration ensures direct delivery to the gastric mucosa. This is arguably the single most well-validated use of BPC-157.
Recommended Peptides
- BPC-157 – primary and most evidence-supported peptide for gastric ulcers; heals NSAID-induced mucosal damage (even while NSAIDs continue), reverses aspirin-induced gastric lesions, promotes angiogenesis in gastric mucosa, and reduces H. pylori-associated damage; oral dosing (capsule or dissolved in water) for direct mucosal contact; outperforms many conventional ulcer treatments in animal models
Protocols
Related Conditions
Research Summary
BPC-157 is the most studied peptide for gastric ulcer protection. Sikiric et al. reviewed its counteraction of NSAID-induced GI, hepatic, and encephalopathic toxicity (PMID-22950504). BPC 157 stabilizes intestinal permeability and tight junctions (PMID-32445447). All evidence is preclinical.
Related
#condition #gastrointestinal